pharmtrace was founded in 2006 by Wolf S. Richter, MD PhD. It is an owner-managed clinical research organization (CRO). As former Head and Executive Director of Global Medical Development, Diagnostic Imaging / Radiopharmaceuticals and Head of Digital Image Management at Bayer Schering AG, and with more than 12 years clinical work as a nuclear medicine physician in Charité (Berlin, Germany), Wolf combines more than 30 years of clinical experience in academic and pharmaceutical research and development.
Since 2006, pharmtrace has grown from 1 employee (the founder) to >15 in 2020. Growth has been financed, exclusively, by retained earnings and repeat business. The pharmtrace team consists of graduate level professionals, scientists and medical doctors with extensive and ongoing training in practical operational aspects necessary for the conduct of GCP clinical trials. The pharmtrace team is expanded by a network of professional and qualified CRAs, as well as a worldwide network of radiological and nuclear medicine specialists and key opinion leaders.
pharmtrace has achieved consistent annual increases in the number and complexity of assignments won. Assignments included consultancy work, comprehensive clinical trials management, imaging core lab services, and support in the regulatory submission phase. Customers of pharmtrace include biotech and academia, as well as internationally acting pharmaceutical companies and device manufacturers. pharmtrace is committed to delivering results that are relevant from a scientific and regulatory perspective. At pharmtrace, each project is handled individually to find the best procedures and processes – while adhering to all GCP and regulatory authority requirements.
With a yearly employee turnover rate of less than 5% since its founding, pharmtrace provides continuity, expert knowledge, and operational excellence for your clinical project.